Literature DB >> 8765924

[Treatment of pulmonary lymphangioleiomyomatosis using a GnRH agonist].

S Desurmont1, C Bauters, M C Copin, D Dewailly, A B Tonnel, B Wallaert.   

Abstract

Pulmonary lymphangioleiomyomatosis is a rare and exclusively female disease which is oestrogen dependent and has a serious prognosis. We present two cases of young women aged 30 and 33 with the same clinical history of renal angiomyolipomas and recurring pneumothoraces. The computerised tomographic scans of the lung were strongly suggestive of LAM (there were fine wall cysts which were disseminated throughout both lung fields). The histological proof was provided by lung biopsy which was carried out during a thoracotomy for pleurectomies. The first patient who is currently asymptomatic and in excellent general health, was treated for three months with tamoxifen (Nolvadex), then for 20 months with 3.75 mg per month of triptoline (Decapeptyl), an agonist of GnRH. The second patient received triptoline in the same dose. After 40 months of treatment this patient was asymptomatic with satisfactory lung function tests. Agonists of GnRH (gonadotropic release hormone) seem to provide a useful alternative in the treatment of LAM.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765924

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  5 in total

1.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

2.  Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.

Authors:  Sergio Harari; Roberto Cassandro; Iacopo Chiodini; Jacopo Chiodini; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Chest       Date:  2007-12-10       Impact factor: 9.410

Review 3.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

4.  Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis.

Authors:  Jack L Arbiser; Baskaran Govindarajan; Xianhe Bai; Hiroaki Onda; Andrius Kazlauskas; So Dug Lim; Mahul B Amin; Lena Claesson-Welsh
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

5.  Lymphangiomyomatosis discovered by massive hemoptysis during general anesthesia -A case report-.

Authors:  Deokkyu Kim; Sung Nyu Lee; Sang-Kyi Lee; Jeongwoo Lee
Journal:  Korean J Anesthesiol       Date:  2012-04-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.